TOP > 外国特許検索 > TRANSMUCOSAL ABSORPTION PROMOTER FOR LOW-MOLECULAR PHARMACEUTICAL COMPOUND

TRANSMUCOSAL ABSORPTION PROMOTER FOR LOW-MOLECULAR PHARMACEUTICAL COMPOUND NEW

外国特許コード F180009517
整理番号 (S2017-0303-N0)
掲載日 2018年11月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP004702
国際公開番号 WO 2018147437
国際出願日 平成30年2月9日(2018.2.9)
国際公開日 平成30年8月16日(2018.8.16)
優先権データ
  • 特願2017-023567 (2017.2.10) JP
発明の名称 (英語) TRANSMUCOSAL ABSORPTION PROMOTER FOR LOW-MOLECULAR PHARMACEUTICAL COMPOUND NEW
発明の概要(英語) The present invention addresses the problem of providing a transmucosal absorption promoter for low-molecular pharmaceutical compounds. The problem is solved by providing a transmucosal absorption promotor for low-molecular pharmaceutical compounds, the promotor containing a cell membrane-penetrating peptide.
従来技術、競合技術の概要(英語) BACKGROUND ART
New drug candidate compound is found in recent years, reduced membrane permeability, pharmaceutical, pharmacokinetic properties such as having a problem is pointed out that in many cases.Biopharmaceutics Classification System (BCS) 3 are not classified into the class is 4, and the like express Breast Cancer Resistance Protein (BCRP) P-glycoprotein (P-gp) the gastrointestinal tract of a substrate transporter can be a medicament outlet, low membrane permeability and the main factors.May be a good candidate compound, transmucosal absorption is significantly reduced, if dynamic control is difficult, during development the dropout rate increases.Anti-cancer agent such as an excessive rise in the development cost can be suppressed, the cost of medical care costs or country agent in order to reduce the, candidate pharmaceutical compounds to improve the properties of transmucosal absorption, increase the probability of successful research and development of pharmaceuticals is possible to construct the base technology is essential.
A substrate transporter and the discharge agent insoluble drug transmucosal absorption of the absorbent for the purpose of improving, with respect to the transporter to this as the use of a specific inhibitor of the interaction between drugs using the competitive techniques have been attempted.However, these conventional approaches are supposed to be originally provided with a living body is in the foreign matter discharge function to fail, or, to increase or decrease the effect of the drug of the other possibility, from the viewpoint of safety and is not always a universal method.In addition, a drug carrier to encapsulate the nano-particles from the transporter to avoid the perception of a technique has been attempted, cannot necessarily be useful, a preparation method thereof is also complicated.
In recent years, peptide TAT, such as a cell membrane of the various peptide (cell-penetrating peptides (CPPs) ) penetratin used, can facilitate the introduction of the drug in the bio cell has been reported (Non-Patent Document 1).However, these peptides, crosslinking of the drug by the drug used to facilitate transmucosal absorption or in, a protein, a peptide of a relatively high molecular weight to facilitate transmucosal absorption of the drug is large in (Patent Document 1) has.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KOBE GAKUIN EDUCATIONAL FOUNDATION
  • 発明者(英語)
  • Makiko Takeda
  • Kamei Noriyasu
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close